Search

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

Protein Degraders: Changing the Game in Cancer Drug Discovery

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Search

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Partnering in CardioMetabolic Diseases

BI Cares Financial Contributions Program

Dortmund

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

Biosimilars

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

A day of giving back at Pegasus Therapeutic Riding

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

A legacy in the making: Working together to spark meaningful change

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Protein Degraders: Changing the Game in Cancer Drug Discovery

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Partnering in CardioMetabolic Diseases

BI Cares Financial Contributions Program

Dortmund

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

Biosimilars

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

A day of giving back at Pegasus Therapeutic Riding

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

A legacy in the making: Working together to spark meaningful change

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Protein Degraders: Changing the Game in Cancer Drug Discovery

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure